NEKTAR THERAPEUTICS (NKTR)       2.59  -0.02 (-0.77%)

2.59  -0.02 (-0.77%)

US6402681083 - Common Stock

Buy % Consensus

49
Analysts have set a mean price target of 4.5. This target is 73.85% above the current price.
NKTR was analyzed by 15 analysts. The buy percentage consensus is at 49. So analysts seem to be rather neutral about NKTR.
In the previous month the buy percentage consensus was at a similar level.
NKTR was analyzed by 15 analysts, which is quite many. So the average rating should be quite meaningful.

Price Target

Price Low Median Mean High 2.593.034.794.506.30 - 16.99% 85.10% 73.85% 143.24%

Up and Down Grades

Date Firm Action Rating
2022-08-08 JP Morgan Downgrade Neutral -> Underweight
2022-04-18 Mizuho Maintains Neutral
2022-04-18 SVB Leerink Maintains Market Perform
2022-04-18 Goldman Sachs Downgrade Neutral -> Sell
2022-03-09 Oppenheimer Upgrade Perform -> Outperform
2021-11-08 Benchmark Upgrade Hold -> Buy
2021-11-08 SVB Leerink Maintains Market Perform
2021-11-05 Oppenheimer Maintains Perform
2021-09-10 B of A Securities Initiate Neutral
2021-08-06 SVB Leerink Maintains Market Perform
2021-06-28 Stifel Upgrade Hold -> Buy
2021-05-10 SVB Leerink Maintains Market Perform
2021-04-06 SVB Leerink Maintains Market Perform
2021-02-22 Benchmark Downgrade Buy -> Hold

Analyst Ratings Stock Screener Links

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA